Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Synergy Pharmaceuticals Inc    SGYP

SYNERGY PHARMACEUTICALS INC (SGYP)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
0.2789 USD   -2.21%
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
0.2028(c) 0.2365(c) 0.2393(c) 0.2852(c) 0.2789(c) Last
6 909 812 11 381 800 5 836 335 14 832 192 7 372 433 Volume
+3.10% +16.62% +1.18% +19.18% -2.21% Change
More quotes
Financials (USD)
Sales 2018 45,3 M
EBIT 2018 -125 M
Net income 2018 -133 M
Debt 2018 -
Yield 2018 -
Sales 2019 90,8 M
EBIT 2019 -103 M
Net income 2019 -85,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 1,53x
Capi. / Sales2019 0,76x
Capitalization 69,2 M
More Financials
Company
Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts... 
More about the company
Surperformance© ratings of Synergy Pharmaceuticals In
Trading Rating : Investor Rating : -
More Ratings
Latest news on SYNERGY PHARMACEUTICALS IN
01/17NEWS HIGHLIGHTS : Top Financial Services News of the Day
DJ
01/10SYNERGY PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Othe..
AQ
01/03SYNERGY PHARMACEUTICALS : Thinking about buying stock in Apple, Randgold Resourc..
PR
01/02SYNERGY PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Cont..
AQ
2018SYNERGY PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Cont..
AQ
2018Synergy Pharmaceuticals Up 55% on Trulance Progress in Canada
DJ
2018SYNERGY PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Bank..
AQ
2018BAUSCH HEALTH : Enters Into Definitive 'Stalking Horse' Agreement To Acquire Sub..
AQ
2018SYNERGY PHARMACEUTICALS : Announces Agreement for Bausch Health to Acquire Its B..
AQ
2018BAUSCH HEALTH : Former Pharma Highflier Appreciates Bathroom Humor -- Overheard
DJ
More news
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart SYNERGY PHARMACEUTICALS INC
Duration : Period :
Synergy Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNERGY PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 2,00 $
Spread / Average Target 617%
EPS Revisions
Managers
NameTitle
Troy Hamilton Chief Executive Officer & Director
Melvin K. Spigelman Chairman
Gary G. Gemignani Secretary, CFO, Principal Accounting Officer & EVP
Patrick H. Griffin Chief Medical Officer & Executive Vice President
John P. Brancaccio Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SYNERGY PHARMACEUTICALS INC144.86%69
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300